Atlas Trials

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Clinical trial NCT05912517 · RECRUITING

Trial details

NCT number
NCT05912517
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hemolytic Disease of the Fetus and Newborn
Start date
2023-12-20
Primary completion
2027-08-05
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.